抗乙肝胎盘转移因子治疗乙型肝炎肝硬化疗效观察  

The Therapeutic Effect of Anti-HBV Placenta Transfer Factor Injection on liver Cirrhosis Resulting from Chronic Hepatitis B

作　　者：石伟珍[1] 过建春[1] 施军平[1] 王宇芳[1] 荀运浩[1] 

机构地区：[1]浙江省杭州市第六人民医院,310014

出　　处：《医学研究杂志》2008年第3期69-70,共2页Journal of Medical Research

摘　　要：目的观察抗乙肝胎盘转移因子治疗乙型肝炎肝硬化的疗效。方法选择193例并发症已控制的活动性乙型肝炎肝硬化病人,予以抗乙肝胎盘转移因子治疗。治疗24周前后观察患者症状和体征(乏力、肝区疼痛、肝脾大)、生化指标如肝功能(ALT、AST、血清总蛋白、清蛋白、总胆红素、A/G等)、血常规、肝纤维化指标(HA、LN、PⅢP、PIVP)、蛋白电泳等项目。结果治疗24周后患者症状和体征及肝功能、血常规、肝纤维化指标、蛋白电泳等指标均得到改善,且与治疗前比较有显著性差异,P<0.05。结论抗乙肝胎盘转移因子对乙型肝炎肝硬化患者的症状和生化指标有较好的改善作用。Objective To observe the therapeutic effect of anti - HBV placenta transfer factor injection to liver cirrhosis. Methods 193 cases of liver cirrhosis resulting from chronic hepatitis B are administrated anti - HBV placenta transfer factor. The main clinical symptoms and signs （weakness, hepatalgia, hepatosplenomegaly ） , the biochemical markers such as liver function （ALT, AST, serum total protein, albumin, total bilirubin, A/G）, blood routine, fibrosis markers （HA,LN,PⅢP,PⅣP）, and serum protein electrophoresis before and after 24 weeks treatment were analysed. Results The main clinical symptoms and signs, liver function, blood routine, fibrosis markers, serum protein electrophoresis were significantly improved after 24 weeks of treatment. （P 〈 0.05 ）. Conclusions In patients with liver cirrhosis, the anti -HBV placenta transfer factor could improved the clinical symptoms and signs and biochemical markers.

关 键 词：抗乙肝胎盘转移因子 乙型肝炎 肝硬化 疗效 

分 类 号：R512.62[医药卫生—内科学] R512.620.5[医药卫生—临床医学]